Program for Oncopeptides Capital Markets Day December 14th, 2018

STOCKHOLM, Dec. 5, 2018 /PRNewswire/ --

Oncopeptides AB (Nasdaq Stockholm: ONCO) have previously announced that they will host a Capital Markets Day in New York. The program is now available below and on the company website: www.oncopeptides.com / Investors & media / Calendar. The event will be webcasted.

Oncopeptides Capital Markets Day Program

8.30 – 09.00      Introduction to Oncopeptides including a Clinical Trials Overview
                          Jakob Lindberg, CEO of Oncopeptides

9.00 – 09.45      HORIZON and ANCHOR Trials Data Update
                          Professor Paul G Richardson, Dana-Farber Cancer Institute 

9.45 – 9.50        Short Break

09.50 – 10.10    The Evolving Myeloma Treatment Landscape and the Position of
                           Melflufen
                           Paula Boultbee, CCO at Oncopeptides 

10.10 – 10.40    Panel discussion and Q&A
                           Professor Paul G Richardson, Dana-Farber Cancer Institute
                          Jakob Lindberg, CEO of Oncopeptides
                          Christian Jacques, MD, MSc, EVP Clinical Strategy and Chief Scientific Officer
                          Paula Boultbee, CCO at Oncopeptides

10.40 – 11.00    Summary and Conclusions
                          Jakob Lindberg, CEO of Oncopeptides

Registration for investors and analysts: RSVP to Alan Lada at [email protected]

For further information, please contact:

Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: [email protected]
Cell phone: +46 70 853 72 92

This information was submitted for publication at 11.30 CET on December 5, 2018.

About Oncopeptides

Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo®), a peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen compared with established alternative drugs for patients with late-stage multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/oncopeptides-ab/r/program-for-oncopeptides-capital-markets-day-december-14th--2018,c2692981

The following files are available for download:

SOURCE Oncopeptides AB

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED